文献速递泌尿男性生殖肿瘤

恩扎卢胺联合ADT与放疗治疗高危局限或局部晚期前列腺癌的III期试验

ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2026-10-24

ENZARAD (ANZUP 1303) 是一项开放标签III期试验,802例高危局限或局部晚期前列腺癌患者接受根治性放疗和24个月ADT,1:1随机接受恩扎卢胺(160mg/日,24个月)或较老的非甾体抗雄激素(NSAA,6个月)。中位随访92个月,8年无转移生存(MFS-CI)率74% vs 72%(HR 0.88,95%CI 0.67-1.15;P=0.34),无显著改善;预设亚组分析中接受计划性盆腔淋巴结放疗者(N=324)恩扎卢胺可能带来MFS-CI获益(HR 0.47,95%CI 0.29-0.76,Padjusted=0.004)。两组3-5级不良事件均为185例。

要点

  • 恩扎卢胺联合ADT和放疗未显著改善8年MFS-CI(HR 0.88,P=0.34)。
  • 预设亚组中接受盆腔淋巴结放疗者恩扎卢胺可能改善MFS-CI(HR 0.47)。
  • 两组3-5级不良事件发生率相同(各185例)。

核心结论

  • 在高危局限或局部晚期前列腺癌中,与6个月NSAA相比,恩扎卢胺联合24个月ADT和放疗未显著改善8年MFS-CI或OS。

研究设计与样本

  • 开放标签、III期随机试验,802例高危局限或局部晚期前列腺癌患者接受根治性前列腺放疗和24个月ADT,1:1随机接受恩扎卢胺(160mg每日,24个月)或NSAA(6个月)。
  • 主要终点为常规影像(CT和/或99mTc-骨扫描)的无转移生存(MFS-CI)。
  • cN1患者必须接受盆腔淋巴结放疗,cN0患者可选。

主要发现

  • 中位随访92个月,共报告207例MFS-CI事件(恩扎卢胺组98例,NSAA组109例)。
  • 8年MFS-CI率恩扎卢胺组74%,NSAA组72%(HR 0.88,95%CI 0.67-1.15;P=0.34)。
  • 预设亚组分析中,接受计划性盆腔淋巴结放疗者(N=324)恩扎卢胺与可能的MFS-CI获益相关(HR 0.47,95%CI 0.29-0.76,Padjusted=0.004)。
  • 两组3-5级不良事件均为185例。

临床怎么用

  • 对于高危局限或局部晚期前列腺癌,恩扎卢胺联合ADT和放疗不应作为所有患者的默认推荐。
  • 接受计划性盆腔淋巴结放疗的患者可能从恩扎卢胺中获益,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of adding enzalutamide to androgen deprivation therapy (ADT) and radiotherapy for high-risk localized or locally advanced prostate cancer were unknown. METHODS: Open-label, phase 3 trial of definitive prostate radiotherapy with 24 months of ADT and 1:1 randomization to either enzalutamide (160mg daily for 24 months) or an older nonsteroidal antiandrogen (NSAA) for 6 months. The primary endpoint was metastasis-free survival on conventional imaging (MFS-CI) with computerized tomography and/or 99mTc-bone scintigraphy. Radiation to pelvic lymph nodes was required for cN1 disease but optional for cN0. RESULTS: 802 participants were randomized. After a median follow-up of 92 months, 207 MFS-CI events were reported (98 enzalutamide, 109 NSAA) with 8-year MFS-CI rates 74% vs 72%, hazard ratio [HR] 0.88, 95% confidence interval [CI], 0.67 to 1.15; P=0.34). Prespecified subgroup analyses noted enzalutamide was associated with a possible MFS-CI benefit in the subgroup undergoing planned pelvic nodal radiotherapy, N=324 (HR 0.47, 95% CI: 0.29 to 0.76 Padjusted =0.004). Grade 3-5 adverse events were reported in 185 participants in each arm. CONCLUSIONS: The use of enzalutamide rather than NSAA in addition to radiotherapy and ADT for 2 years showed no significant MFS-CI or OS improvement at 8 years.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Williams S, Sweeney CJ, Thomas H, et al. ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer. J Clin Oncol. 2026. PMID: 42921729. doi:10.1200/JCO-26-01794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。